Disease · MONDO_0006382

poorly differentiated thyroid gland carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. poorly differentiated thyroid gland carcinoma. Diseases, record MONDO_0006382. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006382

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: poorly differentiated thyroid gland carcinoma; Open Targets
Open Targets ID: MONDO_0006382; Open Targets
Other names: insular carcinoma, poorly differentiated carcinoma of the thyroid gland, poorly differentiated carcinoma of thyroid gland, poorly differentiated thyroid carcinoma, poorly differentiated thyroid gland cancer, thyroid gland poorly differentiated carcinoma; Open Targets
Disease Ontology: DOID:3972; Disease Ontology
NCI Thesaurus: C6040; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 35 of its 37 drugs, from ClinicalTrials.gov; Open Targets

Drugs37

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LENVATINIB	CHEMBL1289601	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BECOTATUG VEDOTIN	CHEMBL6068210	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BUPARLISIB	CHEMBL2017974	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 37

See all 37 drugs

Targets101

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	3	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
RET	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET	3	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	2	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	2	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets

1 to 10 of 101

See all 101 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03002623	CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer	Phase 2	7	2018-12-21	Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer	FIMEPINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT01813136	Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma	Phase 2	168		Thyroid Carcinoma	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT07068542	Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer	Not applicable	94		Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma	SACITUZUMAB TIRUMOTECAN, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06482086	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer	Phase 2	75		Locally Advanced Thyroid Gland Carcinoma	CABOZANTINIB, CATEQUENTINIB, CM-4307, DABRAFENIB, ENTRECTINIB, EVEROLIMUS, LAROTRECTINIB, LENVATINIB, PRALSETINIB, RIVOCERANIB, SORAFENIB, TRAMETINIB, VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT07235566	MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC	Phase 2	60		Thyroid Cancer	BECOTATUG VEDOTIN, PUCOTENLIMAB	Its record names the disease	ClinicalTrials.gov
NCT03181100	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	Phase 2	50		Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma	ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB, PACLITAXEL, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT01830504	A Multicenter Phase II Pilot Open Label	Phase 2	47		Thyroid Cancers	BUPARLISIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06959511	Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery	Phase 2	45		Neoadjuvant Treatment, Thyroid Cancer	ZANZALINTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06970353	Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer	Phase 2	40		Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation	TUNLAMETINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06713057	Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer	Phase 2	20		Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, FLUOROURACIL, GEMCITABINE, PACLITAXEL, PEMETREXED, VINDESINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Anaplastic Thyroid Cancer vs Poorly Differentiated/Variants of Thyroid Cancer: deaths from any cause	2 of 4	1 of 3	7	NCT03002623	Trial comparisons
Anaplastic Thyroid Cancer vs Poorly Differentiated/Variants of Thyroid Cancer: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)	4 of 4	3 of 3	7	NCT03002623	Trial comparisons
Anaplastic Thyroid Cancer vs Poorly Differentiated/Variants of Thyroid Cancer: serious adverse events	2 of 4	1 of 3	7	NCT03002623	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40304938	DERIVED	1	PubMed
39446377	DERIVED	1	PubMed
34509954	DERIVED	1	PubMed
33720068	DERIVED	1	PubMed
30105951	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006382

GET https://conductscience.org/api/diseases/v1/MONDO_0006382/drugs?page=2

API reference For AI assistants